Skip to main content

Table 1 Patient characteristics

From: Phase I/II study of first-line irinotecan combined with 5-fluorouracil and folinic acid Mayo Clinic schedule in patients with advanced colorectal cancer

Characteristics*

Phase I (n = 14)

Phase II (n = 49)

Eligible

14 (100%)

45 (92%)

Evaluable

11 (79%)

36 (73%)

Median age (range) years

59.0 (30.0–69.0)

63.0 (37.0–71.0)

Sex

   Male

7 (50%)

33 (67%)

   Female

7 (50%)

16 (33%)

WHO performance status

   0

4 (29%)

14 (29%)

   1

10 (71%)

31 (63%)

   2

0

4 (8%)

Primary tumour site

   Colon

9 (64%)

17 (35%)

   Rectum

4 (29%)

22 (45%)

   Colon rectosigmoid

1 (7%)

10 (20%)

Organ involved

   Median number

2 (1–4)

2 (1–4)

   Liver

10 (71%)

42 (86%)

   Lung

6 (43%)

17 (35%)

   Lymph node

1 (7%)

10 (20%)

   Other soft tissue

0

11 (22%)

   Abdominal cavity

2 (14%)

3 (6%)

   Peritoneum

1 (7%)

0

   Bone

1 (7%)

0

   Skin

0

1 (2%)

   Other

2 (14%)

5 (10%)

Prior therapy

   Surgery

12 (86%)

42 (86%)

   Radiotherapy

3 (21%)

14 (29%)

   Adjuvant chemotherapy

4 (29%)

12 (24%)

   Surgery + radiotherapy

3 (21%)

12 (24%)

   Surgery + chemotherapy

4 (29%)

12 (24%)

   Radiotherapy + chemotherapy

2 (14%)

7 (14%)

   Surgery + radiotherapy + chemotherapy

2 (14%)

7 (14%)

  1. *N (%) unless otherwise stated. WHO = World Health Organization.